Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DyNAMIc: Adaptive Therapy in Melanoma
NCT06470880Phase 2Not yet recruiting
- Sponsor
- The Christie
- Start
- Jun 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of encorafenib, binimetinib in cutaneous melanoma (CM), sponsored by The Christie. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
encorafenibbinimetinib
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on NCT06470880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06470880.